Drug
Phase I 177lu LU Xt033
Phase I 177lu LU Xt033: highest development phase Phase 1/2, developed by Sinotau Pharmaceutical Group. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Sinotau Pharmaceutical Group
Trials
| Drug | Phase | Indication |
|---|---|---|
| Phase I:[177Lu]Lu-XT033 Injection NCT06081686 | Phase 1/2 | Prostate Cancer |
Latest
No recent events.
Follow Phase I 177lu LU Xt033 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.